Mayo Clinic and ASU MedTech Accelerator boosts health startups

The partnership propels a new cohort of next-generation medical technology and service startups forward with one-of-a-kind tools and resources.

Few things have better illustrated the need for innovative medical technologies than the COVID-19 pandemic. The Mayo Clinic and ASU MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, was designed to help empower medical startups to better navigate challenges while bringing forth life-changing health innovations. The second cohort of this program is set to launch March 30, 2021.

Continue reading

Life365 Adds AliveCor’s Personal EKG Technology to their Virtual Care Platform

SCOTTSDALE, AZ, March 30, 2021— Life365, a leading virtual care platform provider, announced its integration of products from AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, to enhance their remote cardiac monitoring solutions for healthcare consumers and patients located outside traditional care settings.

Continue reading

850 PBC Opens on the Phoenix Biomedical Campus

Located adjacent to ASU’s downtown campus, the Phoenix Biomedical Campus (PBC) Innovation Center expands the downtown biomedical corridor to the northern edges of the urban core. Designed to integrate research, entrepreneurial activity, and corporate engagement, the building offers opportunities for meaningful collaboration with the building tenants and community.Continue reading

Equine Amnio Solutions Signs Exclusive Agreement For Distribution Of RenoVō®, A Next-Generation Equine Regenerative Product

ARGYLE, Texas, March 25, 2021 /PRNewswire/ — Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation equine regenerative products, announced today that Covetrus, a global leader in animal-health technology and services, will be the exclusive distributor of the RenoVō® equine allograft throughout the United States.

Continue reading

CND Life Sciences Closes Series Seed Funding Round

Innovators of the Syn-One Test™ Building Market Presence and Infrastructure

PHOENIX, AZ — March 23, 2021 — CND Life Sciences, Inc. (https://cndlifesciences.com/), an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, announced today the closing of a $2.4 million series seed financing round. HonorHealth, a local health system serving 1.6 million people in the greater Phoenix area, joined several experienced financial investors in funding the round.

Continue reading

New Study Analyzes Potential Impact of Various Drug Pricing Proposals

The Council of State Bioscience Associations (CSBA) today, released data analyzing the potential impact of various drug pricing proposals on patient access to lifesaving medicines, future biomedical innovation, and the economic health of the life sciences industry. 

The study, which was conducted by Vital Transformation, an international health economics firm, examines the negative effects of bills like “Lower Drug Costs Now Act of 2019” and other foreign reference pricing models had they been enacted. 

Continue reading

AZBio Health Innovation Spotlight Public Information Campaign Kicks Off with Vaccine Information

The Sonoran Living Health Innovation Spotlight Public Information Campaign is designed to tackle one of our bioscience industry’s greatest challenges, the “Who Knew” Effect.

Arizona life science innovators are working to discover, develop, and deliver life saving and life changing innovations.

In 2021, AZBio is pleased to partner with ABC15 and CW61 to share quick Sonoran Living Health Innovation Spotlights during the morning and evening news hours along with longer segments on Sonoran Living periodically during 2021 to help our community learn more about the work of Arizona’s healthcare innovators. Each segment touches on a public health challenge or opportunity and spotlights an Arizona life science company’s work to create a solution.

Continue reading

Investigational AstraZeneca vaccine prevents COVID-19

Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization. The independent Data and Safety Monitoring Board (DSMB) overseeing the trial identified no safety concerns related to the vaccine. The United Kingdom-based global biopharmaceutical company AstraZeneca developed the vaccine and led the trial as regulatory sponsor.Continue reading